Renhe Pharmacy Co.,Ltd (000650.SZ) has a MoatMap StockRank of 96/100 based on Quality (74/100), Value (67/100), and Momentum (48/100) factor scores. The current signal is STRONG BUY. Renhe Pharmacy is a Chinese retail OTC drug manufacturer. It lacks any alignment with our high-conviction CDMO pricing power theme, operating in a highly fragmented and regulated domestic consumer market.
Renhe Pharmacy is a prominent pharmaceutical company specializing in the manufacture and distribution of over-the-counter (OTC) medicines, traditional Chinese medicines, and healthcare products. The company possesses a highly recognized brand portfolio and an extensive distribution network covering hundreds of thousands of retail pharmacies across China. It operates as a highly resilient, marketing-driven consumer healthcare leader with stable cash flows.
| Price | $0.76 |
| Market Cap | $1.1B |
| P/E (TTM) | 20.27 |
| P/E (Forward) | 8.64 |
| Price/Book | 1.14 |
| Return on Equity | 6.6% |
| Return on Invested Capital | 9.5% |
| Debt/Equity | 0.03 |
| Gross Margin | 36.5% |
| Operating Margin | 21.2% |
| Revenue Growth | 14.6% |
| Dividend Yield | 2.9% |
| Free Cash Flow | $15M |
Renhe Pharmacy Co.,Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).